NON-ALCOHOLIC FATTY LIVER DISEASE AND HYPERTENSION: CLINICAL VARIABILITY OF COMORBIDITY
PDF

Keywords

non-alcoholic fatty liver disease, NAFLD, hypertension, NAFLD with HT, NAFLD comorbidity, clinical variability, clinical manifestation

Abstract

Introduction. Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases; and considerable attention is paid to the comorbidity of NAFLD with hypertension (HT), which affects around one-third of the world's population. The combination of NAFLD with hypertension has been suggested to have a mutual potentiating effect, and hypertension affects the severity of NAFLD. The purpose: to study the features of the clinical manifestation of NAFLD in patients with hypertension. Materials and methods. The study included 115 patients with NAFLD at the stage of nonalcoholic steatohepatitis. The main group consisted of 63 patients with NAFLD and HT, the comparison group included 52 patients with isolated NAFLD, and the control group was composed of 20 healthy volunteers. The patients underwent anthropometric measurements, evaluation of biochemical markers of liver functional activity, lipid profile and carbohydrate metabolism changes, C-reactive protein (CRP) levels. Results. A significant increase in the proportion of patients with active complaints in the group of patients with NAFLD with HT (subjective signs of liver damage, manifestations of dyspeptic and asthenic syndrome) was detected. Significant differences were found in almost all anthropometric indicators in both groups of patients with NAFLD in comparison with the control group. The level of CRP had significant differences and was 7.90 mg/l (95% CI = 7.96-8.75 mg/l), 6.55 mg/l (95% CI = 6.47-7.57 mg/l) and 2.07 (95% CI = 1.83-2.85 mg/l) in patients with NAFLD and HT, isolated NAFLD and the control group, respectively (p <0.001). Fasting glucose levels were significantly higher in both groups of examined patients with NAFLD compared with controls. Significant differences were found in the levels of total cholesterol, VLDL cholesterol, HDL cholesterol and atherogenic factor in patients with NAFLD depending on concomitant HT. There was no significant difference between LDL cholesterol and triglycerides in the two groups of patients with NAFLD. Conclusions. Based on the obtained data, it can be stated that GC in patients with NAFLD determines important deviations in the clinical manifestation of the disease and can be considered as a trigger factor for the progression of NAFLD.

https://doi.org/10.35339/ic.7.3.131-138
PDF

References

Ampuero, J., Aller, R., Gallego-Duran, R., Crespo, J., Calleja, J.L., Garcia-Monzon, C., … RomeroGomez, M. (2020). Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. Journal of Hepatology, 73(1), 17–25. doi: 10.1016/j.jhep.2020.02.028.

Aneni, E. C., Oni, E. T., Martin, S. S., Blaha, M. J., Agatston, A. S., Feldman, T.,…Nasir K.(2015). Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk. Journal of Hypertension, 33(6), 1207–1214. doi: 10.1097/HJH.0000000000000532. PMID: 25693058.

Babak, O., Zajceva, M. (2018). Ocinjuvannja pokaznykiv kardiogemodynamiky u hvoryh na arterial'nu gipertenziju ta nealkogol'nu zhyrovu hvorobu pechinky zalezhno vid genotypiv polimorfizmu A1166S gena receptora angiotenzynu II pershogo typu [Assessment of cardiac hemodynamics indicators in patients with arterial hypertension and non-alcoholic fatty liver disease depending on angiotensin II type 1 receptor A1166C gene polymorphism]. Zaporozhskyj medycynskyj zhurnal, 20(3), 305–308.

Babak, O. Ya., Prosolenko, K. Î., Klimenko, Ì. I., Panchenko, G. Yu. (2020). Porivnjal'na harakterystyka shem tryvalogo kompleksnogo likuvannja hvoryh na nealkogol'nu zhyrovu hvorobu pechinky u pojednanni z gipertonichnoju hvoroboju [Comparative characteristics of long-term complex treatment regimens for patients with non-alcoholic fatty liver disease in combination with hypertension]. Ukrai'ns'kyj terapevtychnyj zhurnal, (1), 6–14. doi: 10.30978/UTJ2020-1-6.

Bonnet, F., Gastaldelli, A., Pihan-Le Bars, F., Natali, A., Roussel, R., Petrie J. (2017). Gammaglutamyltransferase, fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies. Journal of Hypertension, 35, 493–500.

Fadjejenko, G. D., Kushnir, I. E., Chernova, V. M. (2018). Vzajemozv'jazok mizh rivnemsyrovatkovyh markeriv zapalennja ta metabolichnymy porushennjamy pry nealkogol'nij zhyrovij hvorobi pechinky [The relationship of serum inflammatory markers with metabolic disorders at the non-alcoholic fatty liver disease]. Suchasna gastroenterologija, 5(103), 7–12. doi: 10.30978/MG-2018-5-7.

Fracanzani, A. L., Petta, S., Lombardi, R., Pisano, G., Russello, M., Consonni, D., … Fargion, S.(2017). Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. Clinical Gastroenterology and Hepatology, 15(10), 1604–1611. doi: 10.1016/j.cgh.2017.04.045.

Ilan, Y. (2018). Analogy between non-alcoholic steatohepatitis (NASH) and hypertension: a stepwisepatient-tailored approach for NASH treatment. Annals of gastroenterology, 31(3), 296–304.

Kim, M.J. Non-alcoholic Fatty Liver Disease, Cardio-metabolic Syndrome and Hypertension: OneConcept Fits Multi-systemic Presentations. (2020). Korean Circulation Journal, 50(8), 706–708. doi: 10.4070/kcj.2020.0217.

Liu, P., Tang, Y., Guo, X., Zhu, X., He, M., Yuan, J., … Yao, P. (2018). Bidirectional associationbetween nonalcoholic fatty liver disease and hypertension from the Dongfeng-Tongji cohort study. Journal of the American Society of Hypertension. doi: 10.1016 /j.jash.2018.06.013.

Lonardo, A., Ballestri, S., Marchesini, G., Angulo, P., Loria, P. (2015). Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 47, 181–190.

Lonardo, A., Nascimbeni, F., Mantovani, A., Targher, G. (2017). Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? Journal of Hepatology, 68(2), 335-352. doi: 10.1016/j.jhep.2017.09.021. Epub 2017 Nov 6. PMID: 29122390.

Ma, J., Hwang, S.-J., Pedley, A., Massaro, J. M., Hoffmann, U., Chung, R. T., … Long, M. T. (2017). Bi-directional analysis between fatty liver and cardiovascular disease risk factors. Journal of

Hepatology, 66(2), 390–397. doi: 10.1016/j.jhep.2016.09.022.

Marunchyn, N., Dynnyk, O., Kovalerenko, L. (2017). Zastosuvannja pryncypu mul'typarametrychnogo ul'trazvuku dlja diagnostyky nealkogol'noi' zhyrovoi' hvoroby pechinky v pacijentiv iz cukrovym diabetom 2-go typu [Using the principle of multiparametric ultrasound for the diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus]. Mezhdunarodnyi Endokrinologicheskii Zhurnal, no 13, pp.171–176. doi: 10.22141/2224-0721.13.2.2017.100608.

Oikonomou, D., Georgiopoulos, G., Katsi, V., Kourek, C., Tsioufis, C., Alexopoulou, A., Tousoulis, D. (2018). Non-alcoholic fatty liver disease and hypertension. European Journal of Gastroenterology & Hepatology, 30(9), 979–985. doi: 10.1097/meg.0000000000001191.

Singh, S., Allen, A.M., Wang, Z., Prokop, L.J., Murad, M.H., Loomba, R. (2015). Fibrosis progression in nonalcoholic fatty liver vs. nonalcoholic steatohepatitis: a systematic review and metaanalysis of paired-biopsy studies. Clinal Gastroenterology and Hepatology, 13, 643–654. doi: 10.1016/ j.cgh.2014.04.014.

Tiwari-Heckler, S., Gan-Schreier, H., Stremmel, W., Chamulitrat, W., Pathil, A. (2018). Circulating Phospholipid Patterns in NAFLD Patients Associated with a Combination of Metabolic Risk Factors. Nutrients, 10(5), 649. doi: 10.3390/nu10050649.

Tofano, R. J., Barbalho, S. M., Bechara, M. D., Quesada, K., Mendes, C. G., & Oshiiwa, M. (2017). Hypertension, C Reactive Protein and Metabolic Profile: What is the Scenario in Patients Undergoing Arteriography? Journal of clinical and diagnostic research, 11(8), BC19-BC23. https://doi.org/10.7860/JCDR/2017/26595.10456

Wu, S.-J., Zou, H., Zhu, G.-Q., Wang, L.-R., Zhang, Q., Shi, K.-Q., … Zheng, M.-H. (2015). Increased Levels of Systolic Blood Pressure Within the Normal Range Are Associated With Significantly Elevated Risks of Nonalcoholic Fatty Liver Disease. Medicine, 94(19), e842. doi: 10.1097/md.0000000000000842.

Younes, R., & Bugianesi, E. (2019). NASH in Lean Individuals. Seminars in Liver Disease, 39(1), 86–95. doi: 10.1055/s-0038-1677517.

Zhang, Y., Zhang, T., Zhang, C. (2015). Identification of reciprocal causality between non-alcoholic fatty liver disease and metabolic syndrome by a simplified Bayesian network in a Chinese population. The BMJ, 5, e008204. doi: 10.1136/bmjopen-2015-008204.

Copyright for articles published in the journal is regulated by the License Agreement for the use of a scientific article in the journal, which is concluded between the author of the article (Licensor) and Kharkov National Medical University (Licensee, publisher of the journal "Inter Collegas"). The licensor grants to the Licensee a non-exclusive non-exclusive license for the use of the article (a license that does not exclude the use of the article by the Licensor and the issuance of licenses to others for use of this article) on the terms and for the period specified in the contract. The licensor (the author of the article) grants the Licensee the right to reproduce the article (publication in the journal "Inter Collegas", publication, duplication, duplication or other reproduction of the article without limiting the circulation of copies, each copy of the article must contain the name of the Licensor; Of general information, including the publication of the article in full or in part on the Internet on the journal page, the right to use the metadata of the article (titles, full names of authors, annotations, bibliography eskih materials) through the dissemination and communication to the public, processing and systematization, as well as inclusion in various databases and in-formational system).

The licensor grants the licensee the right to transfer, store and process his personal data (full name, scientific degree, academic title, place of work and position, contact information of the authors) with the purpose of including them in the database in accordance with the Law of Ukraine No. 2297 - VI "on protection of personal data" from 01.06.2010.

Personal data and metadata of the article are provided for their storage and processing in various databases and information systems, including them in analytical and statistical reporting, creating sound relationships between the objects of works of science, literature and art with personal data, etc. on unlimited territory. The licensee has the right to transfer the specified data for processing and storage to third parties provided that such a fact is notified with the provision of information about the third party (name and address) to the Licensor.